The evolution of evaluation of risk for clinically significant prostate cancer

Whatever one may happen to think about the value of the PSA test, we all know that it is very bad at actually telling a doctor or a patient if that patient is at real risk for clinically significant prostate cancer. So, from that perspective …

There is an interesting article on line this morning on the STAT web site by Sharon Begley — a highly respected scientific and medical journalist — dealing with the many new approaches to better evaluation of patients for risk of prostate cancer and whether those patients really need to have a biopsy or not. The article includes specific reference to research to be presented at the upcoming annual meeting of the American Urological Association in Boston.

This is an article that’s well worth reading.

2 Responses

  1. Hi,

    How can I get to this article you are referring to. I haven’t seen a way to get to it.

    Thank you for the info.

    Let me tell you, I follow very closely your comments and your references.

    Have a great day,


  2. Dear Claude:

    Your should just be able to click on the link in the text above. However, if that isn’t working for you here is the full link:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: